Cidofovir in the treatment of poxvirus infections

Antiviral Research

Volumn 55, Issue 1, 2002, Pages 1-13

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Cidofovir; Cowpox; Immunocompromised; Molluscum contagiosum; Monkeypox; Orf; Poxvirus; Smallpox; Vaccinia; Variola

Indexed keywords

2 AMINO 7 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]PURINE; ACICLOVIR; CIDOFOVIR; IDOXURIDINE; METISAZONE; PROBENECID; RIBAVIRIN; ANTIVIRUS AGENT; CYTOSINE; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

COWPOX; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INFECTION PREVENTION; MOLLUSCUM CONTAGIOSUM; NEPHROTOXICITY; NONHUMAN; POXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SMALLPOX; UVEITIS; VACCINIA; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; IMMUNE DEFICIENCY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, INTRANASAL; ANIMAL; ANTIVIRAL AGENTS; COMPARATIVE STUDY; CYTOSINE; DISEASE MODELS, ANIMAL; DNA, VIRAL; HUMAN; IMMUNOCOMPROMISED HOST; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; ORGANOPHOSPHORUS COMPOUNDS; POXVIRIDAE; POXVIRIDAE INFECTIONS; ANIMALS; HUMANS; PHOSPHONIC ACIDS;

CYTOMEGALOVIRUS; DNA VIRUSES; POXVIRIDAE; VACCINIA VIRUS; VARIOLA; VARIOLA VIRUS;

EID: 0035997915     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00008-6     Document Type: Review

References (44)

1. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells
2. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge
3. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells
4. Metabolism of 1-(S)-3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in human embryonic lung cells
5. Uveitis in patients treated with intravenous cidofovir
6. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells
7. Topical cidofovir for severe molluscum contagiosum
8. Therapeutic potential of cidofovir (HPMPC, Vistide®) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus)
9. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections
10. In search of a selective antiviral chemotherapy
11. Antiviral agents that are active against CMV: Potential of cidofovir for the treatment of CMV and other virus infections
12. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
13. A novel selective broad-spectrum anti-DNA virus agent
14. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines
15. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo
16. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream
17. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonyl-methoxy)propyl]cytosine
18. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox
19. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient
20. Progressive vaccinia treated with ribavirin and vaccinia immune globulin
21. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys
22. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial
23. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS
24. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir
25. Parapoxviruses are strongly inhibited in vitro by cidofovir
26. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice
27. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)-purine for treatment of vaccinia virus (orthopoxvirus) infections in mice
28. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC) in vitro
29. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG)
30. Protective effect of 5-iodo-2′-deoxyuridine (IDU) against vaccinia virus infections in SCID mice
31. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
32. Clinical use of cidofovir
33. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir
34. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir
35. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir
36. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice
37. Cidofovir in the treatment of HPV-associated lesions
38. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection
39. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: The HPMPC peripheral cytomegalovirus retinitis trial
40. Topical cidofovir. A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1
41. Oral pharmacokinetics and preliminary toxicology of 1-O-hexadecyloxypropyl-cidofovir in mice
42. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation
43. Topical and intralesional cidofovir: A review of pharmacology and therapeutic effects
44. Topical cidofovir for molluscum contagiosum in children